There are a number of appealing bargains out there on the ASX share market. I think investors have lots of great options to buy this month.
No-one can say when this volatility will end, not even the US President Trump. It could take a bit of time for the full capacity of oil tanker traffic to return to the Strait of Hormuz and for the OPEC countries affected to return their production back to full flow. I’m not going to make any major predictions – all I can see is the lower share prices that we can buy at.
Prices could go lower or higher in the coming weeks from here, but I’m liking what I’m seeing with the following ASX share investments.
Pro Medicus Ltd (ASX: PME)
This healthcare technology business provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide.
Incredibly, the Pro Medicus share price has dropped by more than 50% in the past six months, despite ongoing strong revenue and net profit growth in the latest result and further good contract news.
On 9 March 2026, the business announced a $31 million 5-year renewal with Medstar for the full suite of Visage 7 modules. It also announced a $9 million 5-year viewer renewal with Zwanger-Pesiri. The Medstar contract renewal includes Visage 7 Cardiology.
There are so many positives from this, after all of the negativity surrounding possible future AI impacts.
It showed that clients are willing to renew on long contracts, it shows they want to sign up for cardiology (a growth avenue for Pro Medicus), and they are will to pay more for the software (a strong organic growth tailwind).
Medstar is the largest health system in Maryland and Washington DC. Medstar was the first fully cloud deployed customer and has grown considerably since the initial go-live.
I think the ASX share has a promising future of profit growth ahead and now the valuation seems much more reasonable.
VanEck Morningstar Wide Moat ETF (ASX: MOAT)
I’m a big fan of owning businesses that have strong competitive advantages for the long-term, as I’d expect their profit to be capable of steady growth over time – a great driver of higher share prices.
This exchange-traded fund (ETF) looks for the US businesses, not ASX shares, with the strongest economic moats that are expected to last many years, enabling strong profits during that period.
The MOAT ETF may not have a portfolio full of tech stocks, but perhaps diversification is a positive considering the uncertainty surrounding increasing AI usage.
Time will tell how it performs in the long-term from here, but since inception in June 2025, it has returned an average of 14.4%.
Currently, its biggest investments include Huntington Ingalls Industries, Bristol-Myers Squibb, Idex and United Parcel Service.
